Skip to main content
. 2019 Nov 4;9:15908. doi: 10.1038/s41598-019-52205-6

Figure 2.

Figure 2

Forest plot of (a) primary outcome of the current meta-analysis, showing significant improvements in the overall severity of attention-deficit/hyperactivity disorder (ADHD) after methylphenidate treatment compared to that in placebo groups (Hedges’ g = 0.878, 95% CI = 0.612 to 1.143, p < 0.001), and (b) secondary outcome of the current meta-analysis, indicating insignificant difference in safety profile between methylphenidate and placebo treatments as assessed by drop-out rate (odds ratio = 1.679, 95% CI = 0.681 to 4.138, p = 0.260) and rate of treatment discontinuation due to adverse events (odds ratio = 4.815, 95% CI = 0.981 to 23.628, p = 0.053).